Effect of administrated activity, admission number and TSH level on radiation retention curve of patients taking iodine-131 therapy for differentiated thyroid carcinoma: Looking beyond established regulations

سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 310

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IRJNM-26-1_008

تاریخ نمایه سازی: 21 بهمن 1398

چکیده مقاله:

Introduction: Retention of I-131 in the body of patients with differentiated thyroid carcinoma (DTC) has a direct effect on therapeutic outcome of radioiodine therapy. There are several factors that may influence retention time of radioiodine in the body of these patients. In this study we are going to assess effects of administered radioiodine activity, serum thyroid stimulating hormone (TSH) level and also admission/administration number on the retention of I-131 in the body of DTC patients. Methods: Number of 92 DTC patients, with different TSH levels ranged from 32 mIU/ml to 250 mIU/ml, was treated with different I-131 activities ranged from 1850 MBq to 7400 MBq. They received one, two or three sessions of radioiodine therapy based on severity of cancer. Post-therapy dosimetry for all the patients was performed immediately, 6 hours, 12 hours, 24 hours and one week after the administration of  activity to calculate clearance rate of the I-131. Results:Basedon our observations,there wasa direct correlation between administered radioiodine activities to the patients and clearance rate of the activity from their bodies. Also, those patients who had been admitted for the third time to receive their third radioiodine administration had higher clearance rate as compared to those who had their first or second admissions. TSH level above 32 mIU/ml did not show any effect on clearance rate of I-131. Conclusion: Based on our findings, clearance rate of I-131 is affected by amount of administered radioiodine activities to the patients and number of radioiodine therapy sessions, but serum TSH level above 32 mIU/ml had no effect on this quantity.

نویسندگان

Masoud Moslehi

Department of Nuclear Medicine, Seyedoshohada Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

Ali Mahmoud-Pashazadeh

The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

Rahim Tahmasebi

Department of Biostatistics, School of Public Health, Bushehr University of Medical Sciences, Bushehr, Iran|Department of Health Promotion, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr,

Majid Assadi

The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Burns WR, Zeiger MA. Differentiated thyroid cancer. Semin Oncol. 2010 ...
  • Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW. ...
  • Vaisman F, Corbo R, Vaisman M. Thyroid carcinoma in children ...
  • Vrachimis A, Riemann B, Gerss J, Maier T, Schober O. ...
  • Taylor A, Schuster DM, Alazraki N. A clinicians guide to ...
  • Kwong N, Marqusee E, Gordon MS, Larsen PR, Garber JR, ...
  • Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, ...
  • Baranauskas Z, Valuckas KP, Tiskevicius S. Outcomes of long-term combined ...
  • Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to ...
  • Carballo M, Quiros RM. To Treat or Not to Treat: ...
  • Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, ...
  • Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, ...
  • Verburg FA, Lassmann M, Mäder U, Luster M, Reiners C, ...
  • Papadimitriou D, Kottou S, Oros L, Ilias I, Molfetas M, ...
  • Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, ...
  • Duntas L, Grab-Duntas BM. Risk and prognostic factors for differentiated ...
  • Podoba J. Recombinant human thyrotropin in follow-up of patients with ...
  • Rivkees SA, Mazzaferri EL, Verburg FA, Reiners C, Luster M, ...
  • Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, ...
  • Sabra MM, Grewal RK, Ghossein RA, Tuttle RM. Higher administered ...
  • Mäenpää HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H. ...
  • Ravichandran R, Binukumar J, Saadi AA. Estimation of effective half ...
  • North DL, Shearer DR, Hennessey JV, Donovan GL. Effective half-life ...
  • Venencia CD, Germanier AG, Bustos SR, Giovannini AA, Wyse EP. ...
  • Azizmohammadi Z, Tabei F, Shafiei B, Babaei AA, Jukandan SM, ...
  • Tabei F, Neshandar Asli I, Azizmohammadi Z, Javadi H, Assadi ...
  • Ejeh JE, Adedapo KS. Relationship between TSH level and effective ...
  • Schneider DF, Chen H. New developments in the diagnosis and ...
  • Neshandar Asli I, Siahkali AS, Shafie B, Javadi H, Assadi ...
  • نمایش کامل مراجع